Amgen SupportPlus: Patient Assistance Program for Repatha

Amgen SupportPlus is the manufacturer-sponsored patient assistance program for Repatha (evolocumab). It functions as a centralized navigation resource, connecting patients with appropriate financial support based on their insurance status and offering enrollment in the co-pay card program for commercially insured patients. The program addresses a real barrier: even when Repatha is covered, insurance friction — prior authorization denials, formulary restrictions, high initial co-pays — prevents a substantial fraction of eligible patients from filling their first prescription.

The program is structured by payer type. Commercially insured patients (PPO, HMO, COBRA) can access the co-pay card program through SupportPlus enrollment, potentially reducing out-of-pocket costs to $25 per month. Medicare and Medicaid patients receive coverage navigation support — verification of benefit status, guidance on the Low Income Subsidy pathway for Medicare patients ($12.65 or less per month). Uninsured patients are referred to independent nonprofit patient assistance programs and to the AmgenNow direct-to-patient program at $239/month through a GoodRx partnership.

The program’s practical value is access to a staffed support line (1-844-REPATHA) available Monday through Friday during business hours. For patients navigating a prior authorization appeal or attempting to understand their Medicare formulary, a human touchpoint familiar with the PCSK9 inhibitor reimbursement landscape is more useful than a website alone.

The limitation is that SupportPlus is a manufacturer program — it exists to drive Repatha utilization, and its design reflects that purpose. It does not help patients compare Repatha against evolocumab biosimilar alternatives, and it does not represent an independent patient advocacy function. The practical information about co-pay programs and income-based assistance is accurate and useful within those constraints.

We rate the evidence moderate. Amgen SupportPlus provides a structured access navigation program for Repatha — co-pay cards for commercial patients, subsidy guidance for government-insured patients, and AmgenNow pricing for the uninsured — practically useful for the substantial minority of patients who encounter insurance barriers to filling PCSK9 inhibitor prescriptions.